比较儿童重症支原体肺炎的补充和替代疗法的疗效和安全性：系统评价和荟萃分析方案。
A comparison of efficacy and safety of complementary and alternative therapies for severe mycoplasma pneumonia in children: A protocol for systematic review and meta-analysis.
机构信息
The First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine.
The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China.
出版信息
Medicine (Baltimore). 2021 Feb 19;100(7):e23959. doi: 10.1097/MD.0000000000023959.
BACKGROUND
In recent years, the incidence rate of children with severe Mycoplasma pneumoniae pneumonia (SMPP) is increasing, which poses a great threat to children's life and safety. There are some limitations in the existing drugs for the treatment of SMPP, and the supplementary and alternative therapy of SMPP plays an irreplaceable role in the treatment of this disease. This study will evaluate the efficacy and safety of various complementary and alternative therapies for SMPP by means of mesh meta-analysis. In order to provide the basis for clinical rational use.
METHODS
Two researchers will independently and comprehensively searched the Cochrane Central controlled trials registry, Cochrane Library, PubMed, web of science, EMBASE, CNKI, and Wanfang database to collect randomized controlled trials (RCT) studies on complementary and alternative therapies for SMPP. And the relevant references included in the systematic review/meta-analysis are screened. The retrieval time limit is from the establishment of the database to November 2020. We will use Revman 5.3 software for meta-analysis and use grade to grade the quality of evidence in the net meta-analysis (NMA).
RESULTS
The aim of this study was to compare the efficacy and safety of different complementary and alternative therapies in the treatment of SMPP, with a view to evaluating and ranking different interventions.
CONCLUSION
The supplement and replacement therapy of SMPP can improve the clinical efficacy, relieve the clinical symptoms, improve the quality of life of children, and reduce adverse reactions, which can provide strong support for the rational use of clinicians.
INPLASY REGISTRATION NUMBER
INPLASY2020110079.
背景
近年来，儿童重症肺炎支原体肺炎（SMPP）的发病率呈上升趋势，对儿童的生命安全构成了极大的威胁。现有的治疗 SMPP 的药物存在一定的局限性，SMPP 的补充和替代疗法在该病的治疗中发挥着不可替代的作用。本研究将通过网状 Meta 分析的方法对 SMPP 的各种补充和替代疗法的疗效和安全性进行评价，为临床合理应用提供依据。
方法
由 2 名研究者独立、全面检索 Cochrane 中央对照试验注册库、Cochrane 图书馆、PubMed、Web of Science、EMBASE、中国知网（CNKI）、万方数据库，收集 SMPP 补充和替代疗法的随机对照试验（RCT）研究，并对纳入的系统评价/ Meta 分析的相关参考文献进行筛选。检索时限均为建库至 2020 年 11 月。采用 Revman 5.3 软件进行 Meta 分析，并对网状 Meta 分析（NMA）中的证据质量进行分级评估。
结果
本研究旨在比较不同补充和替代疗法治疗 SMPP 的疗效和安全性，以期对不同干预措施进行评价和排序。
结论
SMPP 的补充和替代疗法可提高临床疗效，缓解临床症状，提高患儿生活质量，减少不良反应，可为临床医生的合理用药提供有力支持。
INPLASY 注册号：INPLASY2020110079。
Zotero 插件